The DCRI and @CVCTForum have launched "Pathway to Prevention," an initiative to build regulatory and clinical pathways for cardiovascular prevention therapies. Three programs multiple stakeholders = closing the gap between science and policy. dcri.org/news/dcri-cvct-laun…#Prevention
ALT A partnership announcement graphic from the Duke Clinical Research Institute and CVCT introducing the "Pathway to Prevention" initiative. The headline reads: "Closing the gap between cardiovascular science and policy." Three program pillars are displayed in separate panels: Pathway to Approval (Regulatory) — building the evidentiary and regulatory framework for prevention indications; Pathway to Access (Payer) — demonstrating economic value and supporting coverage and reimbursement decisions; and Pathway to Adoption (Implementation) — demonstrating long-term value to patients, providers, and payers. The DCRI and CVCT logos appear at the bottom.
HFSA Annual Scientific Meeting early bird registration opens next month! Be the first to know when it opens so you don't miss out on savings and stay updated on all things #HFSA2026
Sign up: 🔗txznq.share.hsforms.com/2DuJ…
Congrats to @PaulaRambarat for her presentation here @escardio HF meeting. Novel insights about GDMT in severe HF. Notable opportunities w SGLT2i. What will the future hold w omecamtiv? Await COMET results #hfcongress26
Need leading experts to design your next global #CV trial? Let's talk. The DCRI brings decades of expertise to every collaboration. Reach out to Claire Beard to schedule a meeting at #ACC26. claire.beard@duke.edu | Learn more: dcri.org/acc#trialdesign#CardioX
And properly evaluate that promising subgroup in follow-up prospective RCT
#COMETHF n=1,800 OM vs PBO in chronic HF w severely reduced LVEF
clinicaltrials.gov/study/NCT…
Powered for CVd, HF event, LVAD transplant,or stroke
Isn’t that how evidence-based medicine is supposed to work?
Classic. When the main trial results disappoint, proponents look to subgroups. Voila. Look at enough and you find positive results.
Like post MI ASA effect turning on astrological sign in ISIS 2.
Want to improve heart failure management in your practice? Adam D. DeVore, MD, MHS summarizes the top takeaways from the latest scientific statement from HFSA and @AAHFN on integrated health technologies, out now in @JCardFail.
#HeartHealth#DigitalHealth#HealthTech@uicnursing
Applications are now open for HFSA Fellowship (FHFSA) — a professional designation recognizing outstanding commitment and leadership in heart failure care.
Earning FHFSA status highlights your contributions to clinical care, research, education, and service within the heart...
Today is the 16th Anniversary of the passing of a @hopkinsheart & @BrighamWomens 🫀leader & legendary figure Dr. Ken Baughman. Many of us consider him to be pivotal in our career paths. We miss KLB greatly.
30 years ago, the #heartfailure specialty had no home.
Today, HFSA is the professional society for the full multidisciplinary team—from cardiologists to nurses, pharmacists, and researchers. Watch how it all began.
#HFSA30Years#HFSA2025
#HFSA2025 plenary & open session now!! Celebrating 30 years!!!! @HFSA@JCardFail
Congratulations to award winners, outgoing president @DukeHFDoc, @NutritionHF for chairing ASM this year & so many others!
The wait is almost over!
We can’t wait to welcome you to #HFSA2025 tomorrow. Get ready for groundbreaking science, networking with colleagues, and the energy of the heart failure community coming together.
Safe travels—we’ll see you in Minneapolis! 💙
ASM Program Chair @NutritionHF shares her hot takes on why YOU should attend #HFSA2025, including highlights on late breaking science. What are you most excited for?
Late Breaking science announced for #HFSA2025! The line-up includes Integra-D Trial, FUTURE-HF, DETECT-HF, FOREST-HCM, MAPLE-HCM, ATTRibute-CM, HELIOS-B, VICTOR Trial, SEISMiC C, SUMMIT Trial, GARDEN TIMI-74, and Danicamtiv Trial. hfsa.org/asm/late-breaking-c…